Heptammune: first-in-class biologic immunomodulator against Inflammatory Bowel Disease
Problem to be solved
Inflammatory Bowel Disease (IBD) is the 3rd major autoimmune disease worldwide, a relapsing disorder acounting for Crohn’s disease and Ulcerative Colitis of unknown etiology and no cure. In this scenario, all IBD drugs have 3 main limitations: limited efficacy, relevant adverse events, low patient adherence, and fall short of expected complete remission.
Technology
Our technology, Heptammune, is a naturally occurring immunomodulatory blood protein analogue acting as immunosuppressor, through a novel mechanism of action (MoA), able to reprogram innate immune cells and resolve inflammation, setting back a stationary state. Heptammune is smaller than a MoAb and can be produced both in prokaryotic or eukaryotic Heptammune route of administration is subcutaneous in a monthly way reporting an improved quality of life.
Autors
Josep Maria Aran Perramon
Technology Readiness Level
TRL5
What are we looking for?
Licensing, co-development or investment for spin-off creation.